Hexima Limited announced the appointment of Dr Nancy Sacco, PhD as Chief Development Officer. Dr Sacco will report to Michael Aldridge, Managing Director & CEO. Prior to this appointment, Dr Sacco held Vice President and Head of Clinical Development roles at Xentria Inc. and AnaptysBio Inc., overseeing programs with monoclonal antibodies for rare and dermatologic diseases. In Dr Sacco's role at Hexima, she will be a senior U.S.-based Hexima representative and will lead the
implementation of Hexima's development strategy and clinical development program. Dr Sacco will also be charged with representing the Company at FDA meetings and with other international regulators, and in interactions with scientific advisors, Key Opinion Leaders, and data review committee members.